Global connectivity and local excitability changes underlie antidepressant effects of repetitive transcranial magnetic stimulation.


Journal

Neuropsychopharmacology : official publication of the American College of Neuropsychopharmacology
ISSN: 1740-634X
Titre abrégé: Neuropsychopharmacology
Pays: England
ID NLM: 8904907

Informations de publication

Date de publication:
05 2020
Historique:
received: 30 04 2019
accepted: 30 01 2020
revised: 23 01 2020
pubmed: 14 2 2020
medline: 24 6 2021
entrez: 14 2 2020
Statut: ppublish

Résumé

Repetitive transcranial magnetic stimulation (rTMS) is a commonly- used treatment for major depressive disorder (MDD). However, our understanding of the mechanism by which TMS exerts its antidepressant effect is minimal. Furthermore, we lack brain signals that can be used to predict and track clinical outcome. Such signals would allow for treatment stratification and optimization. Here, we performed a randomized, sham-controlled clinical trial and measured electrophysiological, neuroimaging, and clinical changes before and after rTMS. Patients (N = 36) were randomized to receive either active or sham rTMS to the left dorsolateral prefrontal cortex (dlPFC) for 20 consecutive weekdays. To capture the rTMS-driven changes in connectivity and causal excitability, resting fMRI and TMS/EEG were performed before and after the treatment. Baseline causal connectivity differences between depressed patients and healthy controls were also evaluated with concurrent TMS/fMRI. We found that active, but not sham rTMS elicited (1) an increase in dlPFC global connectivity, (2) induction of negative dlPFC-amygdala connectivity, and (3) local and distributed changes in TMS/EEG potentials. Global connectivity changes predicted clinical outcome, while both global connectivity and TMS/EEG changes tracked clinical outcome. In patients but not healthy participants, we observed a perturbed inhibitory effect of the dlPFC on the amygdala. Taken together, rTMS induced lasting connectivity and excitability changes from the site of stimulation, such that after active treatment, the dlPFC appeared better able to engage in top-down control of the amygdala. These measures of network functioning both predicted and tracked clinical outcome, potentially opening the door to treatment optimization.

Identifiants

pubmed: 32053828
doi: 10.1038/s41386-020-0633-z
pii: 10.1038/s41386-020-0633-z
pmc: PMC7162876
doi:

Substances chimiques

Antidepressive Agents 0

Types de publication

Journal Article Randomized Controlled Trial Research Support, N.I.H., Extramural Research Support, Non-U.S. Gov't Research Support, U.S. Gov't, Non-P.H.S.

Langues

eng

Sous-ensembles de citation

IM

Pagination

1018-1025

Subventions

Organisme : NIMH NIH HHS
ID : T32 MH019938
Pays : United States
Organisme : NIMH NIH HHS
ID : K23 MH118466
Pays : United States
Organisme : NIMH NIH HHS
ID : T32 MH019908
Pays : United States
Organisme : NIH HHS
ID : DP5 OD028128
Pays : United States
Organisme : NIMH NIH HHS
ID : DP1 MH116506
Pays : United States
Organisme : NIMH NIH HHS
ID : R01 MH126639
Pays : United States
Organisme : NIMH NIH HHS
ID : K23 MH104849
Pays : United States

Références

Sinyor M, Schaffer A, Levitt A. The sequenced treatment alternatives to relieve depression (STAR*D) trial: a review. Can J Psychiatry. 2010;55:126–35.
doi: 10.1177/070674371005500303
Thase ME. The need for clinically relevant research on treatment-resistant depression. J Clin Psychiatry. 2001;62:221–4.
doi: 10.4088/JCP.v62n0401
Noda Y, Silverstein WK, Barr MS, Vila-Rodriguez F, Downar J, Rajji TK, et al. Neurobiological mechanisms of repetitive transcranial magnetic stimulation of the dorsolateral prefrontal cortex in depression: a systematic review. Psychol Med. 2015;45:3411–32.
doi: 10.1017/S0033291715001609
Berlim MT, van den Eynde F, Tovar-Perdomo S, Daskalakis ZJ. Response, remission and drop-out rates following high-frequency repetitive transcranial magnetic stimulation (rTMS) for treating major depression: a systematic review and meta-analysis of randomized, double-blind and sham-controlled trials. Psychol Med. 2014;44:225–39.
doi: 10.1017/S0033291713000512
Fitzgerald PB, Hoy KE, Anderson RJ, Daskalakis ZJ. A study of the pattern of response to rTMS treatment in depression. Depress Anxiety. 2016;33:746–53.
doi: 10.1002/da.22503
George MS, Lisanby SH, Avery D, McDonald WM, Durkalski V, Pavlicova M, et al. Daily left prefrontal transcranial magnetic stimulation therapy for major depressive disorder: a sham-controlled randomized trial. Arch Gen Psychiatry. 2010;67:507–16.
doi: 10.1001/archgenpsychiatry.2010.46
O’Reardon JP, Solvason HB, Janicak PG, Sampson S, Isenberg KE, Nahas Z, et al. Efficacy and safety of transcranial magnetic stimulation in the acute treatment of major depression: a multisite randomized controlled trial. Biol Psychiatry. 2007;62:1208–16.
doi: 10.1016/j.biopsych.2007.01.018
Glasser MF, Coalson TS, Robinson EC, Hacker CD, Harwell J, Yacoub E, et al. A multi-modal parcellation of human cerebral cortex. Nature. 2016;536:171–8.
doi: 10.1038/nature18933
Taylor SF, Ho SS, Abagis T, Angstadt M, Maixner DF, Welsh RC, et al. Changes in brain connectivity during a sham-controlled, transcranial magnetic stimulation trial for depression. J Affect Disord. 2018;232:143–51.
doi: 10.1016/j.jad.2018.02.019
Siddiqi SH, Trapp NT, Hacker CD, Laumann TO, Kandala S, Hong X, et al. Repetitive transcranial magnetic stimulation with resting-state network targeting for treatment-resistant depression in traumatic brain injury: a randomized, controlled, double-blinded pilot study. J Neurotrauma. 2019;36:1361–74.
doi: 10.1089/neu.2018.5889
Ning L, Makris N, Camprodon JA, Rathi Y. Limits and reproducibility of resting-state functional MRI definition of DLPFC targets for neuromodulation. Brain Stimul. 2019;12:129–38.
doi: 10.1016/j.brs.2018.10.004
Philip NS, Barredo J, Aiken E, Carpenter LL. Neuroimaging mechanisms of therapeutic transcranial magnetic stimulation for major depressive disorder. Biol Psychiatry Cogn Neurosci Neuroimaging. 2018;3:211–22.
doi: 10.1016/j.bpsc.2017.10.007
Downar J, Geraci J, Salomons TV, Dunlop K, Wheeler S, McAndrews MP, et al. Anhedonia and reward-circuit connectivity distinguish nonresponders from responders to dorsomedial prefrontal repetitive transcranial magnetic stimulation in major depression. Biol Psychiatry. 2014;76:176–85.
doi: 10.1016/j.biopsych.2013.10.026
Liston C, Chen AC, Zebley BD, Drysdale AT, Gordon R, Leuchter B, et al. Default mode network mechanisms of transcranial magnetic stimulation in depression. Biol Psychiatry. 2014;76:517–26.
doi: 10.1016/j.biopsych.2014.01.023
Fox MD, Buckner RL, White MP, Greicius MD, Pascual-Leone A. Efficacy of transcranial magnetic stimulation targets for depression is related to intrinsic functional connectivity with the subgenual cingulate. Biol Psychiatry. 2012;72:595–603.
doi: 10.1016/j.biopsych.2012.04.028
Speer AM, Kimbrell TA, Wassermann EM, D Repella J, Willis MW, Herscovitch P, et al. Opposite effects of high and low frequency rTMS on regional brain activity in depressed patients. Biol Psychiatry. 2000;48:1133–41.
doi: 10.1016/S0006-3223(00)01065-9
Baeken C, De Raedt R, Van Schuerbeek P, Vanderhasselt MA, De Mey J, Bossuyt A, et al. Right prefrontal HF-rTMS attenuates right amygdala processing of negatively valenced emotional stimuli in healthy females. Behav Brain Res. 2010;214:450–5.
doi: 10.1016/j.bbr.2010.06.029
Kozyrev V, Eysel UT, Jancke D. Voltage-sensitive dye imaging of transcranial magnetic stimulation-induced intracortical dynamics. Proc Natl Acad Sci USA. 2014;111:13553–8.
doi: 10.1073/pnas.1405508111
Keller CJ, Huang Y, Herrero JL, Fini M, Du V, Lado FA, et al. Induction and quantification of excitability changes in human cortical networks. J Neurosci. 2018;38:5384–98.
doi: 10.1523/JNEUROSCI.1088-17.2018
Connors BW, Malenka RC, Silva LR. Two inhibitory postsynaptic potentials, and GABAA and GABAB receptor-mediated responses in neocortex of rat and cat. J Physiol. 1988;406:443–68.
doi: 10.1113/jphysiol.1988.sp017390
Premoli I, Castellanos N, Rivolta D, Belardinelli P, Bajo R, Zipser C, et al. TMS-EEG signatures of GABAergic neurotransmission in the human cortex. J Neurosci. 2014;34:5603–12.
doi: 10.1523/JNEUROSCI.5089-13.2014
Kerwin LJ, Keller CJ, Wu W, Narayan M, Etkin A. Test-retest reliability of transcranial magnetic stimulation EEG evoked potentials. Brain Stimul 2018;11:536–44.
doi: 10.1016/j.brs.2017.12.010
Wu W, Keller CJ, Rogasch NC, Longwell P, Shpigel E, Rolle CE, et al. ARTIST: a fully automated artifact rejection algorithm for single-pulse TMS-EEG data. Hum Brain Mapp. 2018;39:1607–25.
doi: 10.1002/hbm.23938
Chen AC, Oathes DJ, Chang C, Bradley T, Zhou ZW, Williams LM, et al. Causal interactions between fronto-parietal central executive and default-mode networks in humans. Proc Natl Acad Sci USA. 2013;110:19944–9.
doi: 10.1073/pnas.1311772110
First MB, Spitzer RL, Gibbon M, Williams JBW. Structured Clinical Interview for DSM-IV-TR Axis I Disorders, Research Version, Patient Edition. New York, NY: Biometrics Research, New York State Psychiatric Institute; 2002.
Lisanby SH, Husain MM, Rosenquist PB, Maixner D, Gutierrez R, Krystal A, et al. Daily left prefrontal repetitive transcranial magnetic stimulation in the acute treatment of major depression: clinical predictors of outcome in a multisite, randomized controlled clinical trial. Neuropsychopharmacol: Off Publ Am Coll Neuropsychopharmacol. 2009;34:522–34.
doi: 10.1038/npp.2008.118
Prudic J, Haskett RF, Mulsant B, Malone KM, Pettinati HM, Stephens S, et al. Resistance to antidepressant medications and short-term clinical response to ECT. Am J psychiatry. 1996;153:985–92.
doi: 10.1176/ajp.153.8.985
Whitfield-Gabrieli S, Nieto-Castanon A. Conn: a functional connectivity toolbox for correlated and anticorrelated brain networks. Brain Connect. 2012;2:125–41.
doi: 10.1089/brain.2012.0073
Dalgleish T. The emotional brain. Nat Rev Neurosci. 2004;5:583–9.
doi: 10.1038/nrn1432
Fonzo GA, Goodkind MS, Oathes DJ, Zaiko YV, Harvey M, Peng KK, et al. Selective effects of psychotherapy on frontopolar cortical function in PTSD. Am J Psychiatry. 2017;174:1175–84.
doi: 10.1176/appi.ajp.2017.16091073
Lenz M, Galanis C, Muller-Dahlhaus F, Opitz A, Wierenga CJ, Szabo G, et al. Repetitive magnetic stimulation induces plasticity of inhibitory synapses. Nat Commun. 2016;7:10020.
doi: 10.1038/ncomms10020
Huang Y, Hajnal B, Entz L, Fabo D, Herrero JL, Mehta AD, et al. Intracortical dynamics underlying repetitive stimulation predicts changes in network connectivity. J Neurosci. 2019;39:6122–35.
doi: 10.1523/JNEUROSCI.0535-19.2019
Conde V, Tomasevic L, Akopian I, Stanek K, Saturnino GB, Thielscher A, et al. The non-transcranial TMS-evoked potential is an inherent source of ambiguity in TMS-EEG studies. Neuroimage. 2018;185:300–12.
doi: 10.1016/j.neuroimage.2018.10.052
Cash RF, Noda Y, Zomorrodi R, Radhu N, Farzan F, Rajji TK, et al. Characterization of Glutamatergic and GABAA-mediated neurotransmission in motor and dorsolateral prefrontal cortex using paired-pulse TMS-EEG. Neuropsychopharmacology. 2017;42:502–11.
doi: 10.1038/npp.2016.133
Dannlowski U, Ohrmann P, Konrad C, Domschke K, Bauer J, Kugel H, et al. Reduced amygdala-prefrontal coupling in major depression: association with MAOA genotype and illness severity. Int J Neuropsychopharmacol. 2009;12:11–22.
doi: 10.1017/S1461145708008973
Erk S, Mikschl A, Stier S, Ciaramidaro A, Gapp V, Weber B, et al. Acute and sustained effects of cognitive emotion regulation in major depression. J Neurosci. 2010;30:15726–34.
doi: 10.1523/JNEUROSCI.1856-10.2010
Grant MM, White D, Hadley J, Hutcheson N, Shelton R, Sreenivasan K, et al. Early life trauma and directional brain connectivity within major depression. Hum Brain Mapp. 2014;35:4815–26.
doi: 10.1002/hbm.22514
Anderson RJ, Hoy KE, Daskalakis ZJ, Fitzgerald PB. Repetitive transcranial magnetic stimulation for treatment resistant depression: Re-establishing connections. Clin Neurophysiol 2016;127:3394–405.
doi: 10.1016/j.clinph.2016.08.015
Pizzagalli DA. Frontocingulate dysfunction in depression: toward biomarkers of treatment response. Neuropsychopharmacology. 2011;36:183–206.
doi: 10.1038/npp.2010.166

Auteurs

Neir Eshel (N)

Department of Psychiatry and Behavioral Sciences, Stanford University, Stanford, CA, 94305, USA.
Wu Tsai Neurosciences Institute, Stanford University, Stanford, CA, 94305, USA.
Veterans Affairs Palo Alto Healthcare System and the Sierra Pacific Mental Illness Research, Education, and Clinical Center (MIRECC), Palo Alto, CA, 94394, USA.

Corey J Keller (CJ)

Department of Psychiatry and Behavioral Sciences, Stanford University, Stanford, CA, 94305, USA.
Wu Tsai Neurosciences Institute, Stanford University, Stanford, CA, 94305, USA.
Alto Neuroscience, Los Altos, CA, USA.

Wei Wu (W)

Department of Psychiatry and Behavioral Sciences, Stanford University, Stanford, CA, 94305, USA.
Wu Tsai Neurosciences Institute, Stanford University, Stanford, CA, 94305, USA.
Alto Neuroscience, Los Altos, CA, USA.
School of Automation Science and Engineering, South China University of Technology, 510640, Guangzhou, Guangdong, China.

Jing Jiang (J)

Department of Psychiatry and Behavioral Sciences, Stanford University, Stanford, CA, 94305, USA.
Wu Tsai Neurosciences Institute, Stanford University, Stanford, CA, 94305, USA.
Veterans Affairs Palo Alto Healthcare System and the Sierra Pacific Mental Illness Research, Education, and Clinical Center (MIRECC), Palo Alto, CA, 94394, USA.

Colleen Mills-Finnerty (C)

Department of Psychiatry and Behavioral Sciences, Stanford University, Stanford, CA, 94305, USA.
Wu Tsai Neurosciences Institute, Stanford University, Stanford, CA, 94305, USA.
Veterans Affairs Palo Alto Healthcare System and the Sierra Pacific Mental Illness Research, Education, and Clinical Center (MIRECC), Palo Alto, CA, 94394, USA.

Julia Huemer (J)

Department of Child and Adolescent Psychiatry, Medical University of Vienna, Vienna, Austria.

Rachael Wright (R)

Department of Psychiatry and Behavioral Sciences, Stanford University, Stanford, CA, 94305, USA.
Wu Tsai Neurosciences Institute, Stanford University, Stanford, CA, 94305, USA.
Veterans Affairs Palo Alto Healthcare System and the Sierra Pacific Mental Illness Research, Education, and Clinical Center (MIRECC), Palo Alto, CA, 94394, USA.

Gregory A Fonzo (GA)

Department of Psychiatry and Behavioral Sciences, Stanford University, Stanford, CA, 94305, USA.
Wu Tsai Neurosciences Institute, Stanford University, Stanford, CA, 94305, USA.
Veterans Affairs Palo Alto Healthcare System and the Sierra Pacific Mental Illness Research, Education, and Clinical Center (MIRECC), Palo Alto, CA, 94394, USA.
Department of Psychiatry, Dell Medical School, University of Texas at Austin, Austin, TX, USA.

Naho Ichikawa (N)

Department of Psychiatry and Neurosciences, Hiroshima University, Hiroshima, Japan.

David Carreon (D)

Department of Psychiatry and Behavioral Sciences, Stanford University, Stanford, CA, 94305, USA.
Wu Tsai Neurosciences Institute, Stanford University, Stanford, CA, 94305, USA.
Veterans Affairs Palo Alto Healthcare System and the Sierra Pacific Mental Illness Research, Education, and Clinical Center (MIRECC), Palo Alto, CA, 94394, USA.

Melinda Wong (M)

Department of Psychiatry and Behavioral Sciences, Stanford University, Stanford, CA, 94305, USA.
Veterans Affairs Palo Alto Healthcare System and the Sierra Pacific Mental Illness Research, Education, and Clinical Center (MIRECC), Palo Alto, CA, 94394, USA.

Andrew Yee (A)

Department of Psychiatry and Behavioral Sciences, Stanford University, Stanford, CA, 94305, USA.
Veterans Affairs Palo Alto Healthcare System and the Sierra Pacific Mental Illness Research, Education, and Clinical Center (MIRECC), Palo Alto, CA, 94394, USA.

Emmanuel Shpigel (E)

Department of Psychiatry and Behavioral Sciences, Stanford University, Stanford, CA, 94305, USA.
Wu Tsai Neurosciences Institute, Stanford University, Stanford, CA, 94305, USA.
Veterans Affairs Palo Alto Healthcare System and the Sierra Pacific Mental Illness Research, Education, and Clinical Center (MIRECC), Palo Alto, CA, 94394, USA.

Yi Guo (Y)

Department of Neurology, Shenzhen People's Hospital, Shenzhen, China.
2nd Clinical Medical College of Jinan University, Shenzhen, China.

Lisa McTeague (L)

Department of Psychiatry, Medical University of South Carolina, Charleston, SC, USA.

Adi Maron-Katz (A)

Department of Psychiatry and Behavioral Sciences, Stanford University, Stanford, CA, 94305, USA.
Wu Tsai Neurosciences Institute, Stanford University, Stanford, CA, 94305, USA.
Veterans Affairs Palo Alto Healthcare System and the Sierra Pacific Mental Illness Research, Education, and Clinical Center (MIRECC), Palo Alto, CA, 94394, USA.

Amit Etkin (A)

Department of Psychiatry and Behavioral Sciences, Stanford University, Stanford, CA, 94305, USA. amitetkin@stanford.edu.
Wu Tsai Neurosciences Institute, Stanford University, Stanford, CA, 94305, USA. amitetkin@stanford.edu.
Alto Neuroscience, Los Altos, CA, USA. amitetkin@stanford.edu.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH